For instance, avelumab, a fully human IgG1 anti–PD-L1 mAb, was shown to increase the secretion of interferon γ (IFNγ) from anti-tumor immune effector cells, which could enhance both PD-L1 expression and antibody-dependent cellular cytotoxicity (ADCC)-mediated lysis [10]. Here, IFNG is linked to neoplasm.